Shopping Cart
- Remove All
- Your shopping cart is currently empty
Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $67 | In Stock | |
2 mg | $98 | In Stock | |
5 mg | $163 | In Stock | |
10 mg | $288 | In Stock | |
25 mg | $571 | In Stock | |
50 mg | $819 | In Stock | |
100 mg | $1,130 | In Stock | |
1 mL x 10 mM (in DMSO) | $229 | In Stock |
Description | Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction with Ki of 0.149 nM and IC50 between 10 and 20 nM, which can be used in the study of acute leukemia with MLL gene rearrangement. |
Targets&IC50 | Menin-MLL:10-20 nM |
In vitro | METHODS: Primary patient-derived NUP98-r AML cells were treated with Revumenib (SNDX-5613) (2, 46, 125 nM) and cell viability was measured. RESULTS Revumenib inhibited the growth of primary patient-derived NUP98-r AML cells. [3] |
In vivo | SNDX-5613 treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.SNDX-5613 shows in vivo plasma( IC50 : 53 nM) . |
Molecular Weight | 630.82 |
Formula | C32H47FN6O4S |
Cas No. | 2169919-21-3 |
Smiles | CCN(C(C)C)C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(C1)CCN(C[C@H]1CC[C@@H](CC1)NS(=O)(=O)CC)CC2 |
Relative Density. | 1.28 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 60 mg/mL (95.11 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.